A detailed history of Citigroup Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 208,764 shares of IOVA stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
208,764
Previous 138,182 51.08%
Holding current value
$1.78 Million
Previous $1.11 Million 76.9%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.28 - $11.9 $513,836 - $839,925
70,582 Added 51.08%
208,764 $1.96 Million
Q2 2024

Aug 12, 2024

SELL
$7.78 - $14.19 $3.13 Million - $5.7 Million
-401,713 Reduced 74.41%
138,182 $1.11 Million
Q1 2024

May 10, 2024

SELL
$7.59 - $17.47 $1.62 Million - $3.74 Million
-214,013 Reduced 28.39%
539,895 $8 Million
Q4 2023

Feb 09, 2024

SELL
$3.3 - $8.89 $605,586 - $1.63 Million
-183,511 Reduced 19.58%
753,908 $6.13 Million
Q3 2023

Nov 09, 2023

BUY
$4.44 - $8.79 $1.38 Million - $2.73 Million
310,118 Added 49.44%
937,419 $4.27 Million
Q2 2023

Aug 10, 2023

SELL
$5.36 - $9.06 $3.41 Million - $5.76 Million
-635,344 Reduced 50.32%
627,301 $4.42 Million
Q1 2023

May 11, 2023

BUY
$5.53 - $8.22 $4.11 Million - $6.11 Million
743,295 Added 143.12%
1,262,645 $7.71 Million
Q4 2022

Feb 09, 2023

SELL
$5.62 - $10.0 $285,630 - $508,240
-50,824 Reduced 8.91%
519,350 $3.32 Million
Q3 2022

Nov 10, 2022

BUY
$9.53 - $13.11 $864,390 - $1.19 Million
90,702 Added 18.92%
570,174 $5.46 Million
Q2 2022

Aug 10, 2022

BUY
$6.38 - $18.33 $2.48 Million - $7.13 Million
389,174 Added 430.99%
479,472 $5.29 Million
Q1 2022

May 12, 2022

SELL
$12.38 - $19.1 $1.88 Million - $2.9 Million
-151,661 Reduced 62.68%
90,298 $1.5 Million
Q4 2021

Feb 10, 2022

BUY
$16.55 - $27.63 $1.97 Million - $3.29 Million
119,208 Added 97.11%
241,959 $4.62 Million
Q3 2021

Nov 10, 2021

BUY
$20.35 - $26.63 $2.5 Million - $3.27 Million
122,751 New
122,751 $3.03 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.